Boditech Med Acquires 3.03% Stake in 4TEEN4, a German Developer of Products for Cardiogenic Shock

Boditech Med, led by CEO Eui-yul Choi, has disclosed the acquisition of a 3.03% stake in 4TEEN4 Pharmaceuticals GmbH, a specialized company focusing on innovative treatments and diagnostic biomarker development for acute myocardial infarction shock. Alongside this investment, Boditech Med has entered into a licensing agreement for the development and sale of diagnostic biomarker products owned by 4TEEN4.

4TEEN4 is actively developing Procizumab, a DPP3 inhibitor, as a next-generation therapy to prevent the occurrence and mortality of acute myocardial infarction shock. Acute myocardial infarction shock is classified as a serious condition with significant societal and economic burdens due to the lack of effective treatment methods. The DPP3 biomarker developed and owned by 4TEEN4 is utilized for predicting and monitoring myocardial infarction shock in patients with acute coronary syndrome (ACS) and acute heart failure.

Currently, there is no effective drug therapy for myocardial infarction shock, and the mortality rate exceeds 50% within one month after onset, making it a critical condition. DPP3 is recognized as a major cause of myocardial infarction shock affecting over 4 million patients worldwide annually. The global demand for DPP3 rapid diagnostic products is estimated to exceed 50 million units annually.

Eui-yul Choi, CEO of Boditech Med, commented, "Cardiovascular diseases primarily target emergency patients, making them an ideal area for point-of-care diagnostics. In 2023, cardiovascular disease-related products led Boditech Med's growth, with sales increasing by over 40% compared to the previous year. The investment in 4TEEN4 signifies a significant enhancement of collaboration between the two companies in the cardiovascular disease sector. The DPP3 diagnostic product is scheduled for release this year, and it is expected to make a groundbreaking contribution to sales growth starting from 2025."